Ellen Ruud
Oslo University Hospital(NO)University of Oslo(NO)
Publications by Year
Research Areas
Childhood Cancer Survivors' Quality of Life, Acute Lymphoblastic Leukemia research, Family Support in Illness, Neuroblastoma Research and Treatments, Adolescent and Pediatric Healthcare
Most-Cited Works
- → Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial(2018)383 cited
- → Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial(2017)339 cited
- → Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)(2020)141 cited
- → Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification(2009)138 cited
- → Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study(2010)131 cited
- → Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study